Fapon Biotech, a leading life-science organisation, has signed a strategic cooperation agreement with Halodoc, a telehealth startup in Indonesia. This partnership brings together Fapon's expertise in in-vitro diagnostics (IVD) technologies and integrated solutions with Halodoc's strong sales channels and local service provisions.

The partnership aims to enhance the healthcare standards in Indonesia, benefit local communities, and propel the country's IVD industry.

Under the agreement, Fapon will partner with Halodoc in the IVD field by establishing a joint venture to grow the IVD business, and deliver high-quality and user-friendly diagnostic products and health solutions in Indonesia. With 22 years of IVD experience under its belt, Fapon boasts a solid technological foundation and a comprehensive and innovative product portfolio.

Through this collaboration, Fapon will support Halodoc in local IVD product research and manufacturing by providing essential raw materials, reagent solutions, and open-instrument platforms. As the largest telehealth company in Indonesia, Halodoc will leverage its strengths in channels, academia, and industry connections to expedite market expansion, drive consistent business growth, and achieve a win-win result.

Halodoc has been recognized as one of the telehealth platforms making a positive impact on the healthcare sectors and honored to have received the "supervised" status in the Regulatory Sandbox programme by the Ministry of Health of the Republic of Indonesia.